Objective To evaluate the efficacy and safety of antiviral antibody therapies and blood
products for the treatment of novel coronavirus disease 2019 (covid-19). Design Living …

As the coronavirus disease (COVID-19) pandemic led to a global health crisis, there were
limited treatment options and no prophylactic therapies for those exposed to severe acute …

Importance The evidence for benefit of convalescent plasma for critically ill patients with
COVID-19 is inconclusive. Objective To determine whether convalescent plasma would …

Importance Convalescent plasma is a proposed treatment for COVID-19. Objective To
assess clinical outcomes with convalescent plasma treatment vs placebo or standard of care …

Importance COVID-19 is a life-threatening illness for many patients. Prior studies have
established hematologic cancers as a risk factor associated with particularly poor outcomes …

Description: Coronavirus disease 2019 convalescent plasma (CCP) has emerged as a
potential treatment of COVID-19. However, meta-analysis data and recommendations are …

Importance Convalescent plasma (CP) has been generally unsuccessful in preventing
worsening of respiratory failure or death in hospitalized patients with COVID-19 pneumonia …

Patients with hematologic malignancies and recipients of hematopoietic cell transplantation
(HCT) are more likely to experience severe coronavirus disease 2019 (COVID-19) and have …

Abstract Background Neutralizing monoclonal antibodies (MAbs) are a promising therapy for
early coronavirus disease 2019 (COVID-19), but their effectiveness has not been confirmed …

Major changes have occurred in therapeutics for coronavirus-19 (COVID-19) infection over
the past 12–18 mo, most notably in early outpatient therapy. In most cases, solid organ …